Insight Molecular Diagnostics (IMDX) Retained Earnings (2015 - 2026)

Insight Molecular Diagnostics has disclosed Retained Earnings across 12 years of filings, most recently posting -$405.1 million for Q1 2026.

• Retained Earnings for Q1 2026 came in at -$405.1 million, down 13.41% year-over-year; the trailing twelve-month figure through Mar 2026 was -$405.1 million (down 13.41% YoY), and the FY2025 annual result was $86000.0, up 100.02% from the prior year.
• Retained Earnings came in at -$405.1 million for Q1 2026 at Insight Molecular Diagnostics, down from $86000.0 in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $86000.0 in Q4 2025 to a low of -$405.1 million in Q1 2026.
• The 5-year median for Retained Earnings is -$262.1 million (2023), against an average of -$213.3 million.
• Across the five-year window, Retained Earnings tumbled 1379547.37% in 2023 and jumped 100.02% in 2025, its largest moves.
• Insight Molecular Diagnostics' Retained Earnings stood at -$260.7 million in 2022, then soared by 100.02% to $49000.0 in 2023, then sank by 715485.71% to -$350.5 million in 2024, then surged by 100.02% to $86000.0 in 2025, then sank by 471146.51% to -$405.1 million in 2026.
• The last three Retained Earnings figures came in at -$405.1 million (Q1 2026), $86000.0 (Q4 2025), and -$377.8 million (Q3 2025), per Business Quant data.